# Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer

> **NCT00260364** · PHASE1,PHASE2 · COMPLETED · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 44 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle
- **DRUG:** Capecitabine orally days 1 -21
- **DRUG:** Erlotinib 100 mg orally days 1-28
- **DRUG:** Bevacizumab 5 mg/kg intravenously every 2 weeks

## Key facts

- **NCT ID:** NCT00260364
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2016-10-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00260364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00260364, "Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00260364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*